Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tysabri Re-Launch Timing Will Depend On Outcome Of Risk Management Plan

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen Idec/Elan could be prepared to get the multiple sclerosis drug back on the market within weeks of re-approval.

You may also be interested in...



Tysabri Re-Launch Approved With MRI Requirement

FDA clears Biogen Idec’s multiple sclerosis therapy to return to market under a special distribution program.

FDA Re-Approves Tysabri, Recommends Second-Line Use

Biogen Idec expects to re-launch the multiple sclerosis therapy in July.

Tysabri Re-Launch Approved With MRI Requirement

FDA clears Biogen Idec’s multiple sclerosis therapy to return to market under a special distribution program.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064170

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel